Stock Analysis, Dividends, Split History

FOSL / Fossil Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,211.03
Enterprise Value ($M)1,212.80
Book Value ($M)514.97
Book Value / Share10.43
Price / Book2.30
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 48,643,000
Common Shares Outstanding 48,645,361
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.46
Return on Assets (ROA)-0.22
Return on Equity (ROE)-0.47
Balance Sheet (mrq) ($M)
Quick Ratio1.13
Current Ratio2.11
Income Statement (mra) ($M)
Sales Revenue Net2,788,163,000.00
Operating Income-424.28
Net Income-473.56
Earnings Per Share Diluted-9.87
Earnings Per Share Basic-9.87
Cash Flow Statement (mra) ($M)
Cash From Operations179.54
Cash from Investing-24.72
Cash from Financing-24.72
Identifiers and Descriptors
Central Index Key (CIK)883569
Related CUSIPS
034988V10 349882100 34988V906 34988V956

Split History

Stock splits are used by Fossil Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Related News Stories

Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?

2h zacks
Launched on 05/16/2017, the IQ Chaikin U.S. Small Cap ETF (CSML - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market. (11-0)

Wednesday’s Biggest Winners and Losers in the S&P 500

2018-08-08 247wallst
August 8, 2018: The S&P 500 closed flat at 2,857.77. The DJIA closed flat at 25,583.55. Separately, the Nasdaq was flat at 7,888.33. (11-0)

Fossil (FOSL) Stock Up on Q2 Earnings Beat, Watch Sales Drop

2018-08-08 zacks
Fossil Group Inc. (FOSL - Free Report) released second-quarter 2018 results yesterday after the closing bell, with earnings beating the Zacks Consensus Estimate for the fifth straight time and improving year over year. Consequently, shares of the company gained 4.4% during yesterday’s after-market trading session. However, the top line declined from the year-ago quarter’s figure, thanks to dismal traditional watch sales. (24-0)

Fitbit Stock Is Being Underestimated by Wall Street

2018-08-06 investorplace
Quite often, Wall Street focuses on the proverbial trees and ignores the forest. That’s certainly the case with FIT stock in the wake of the company’s second-quarter results reported Wednesday. The Street seems fixated on worries about Fitbit’s (NYSE: FIT) conservative full-year guidance, gross margins, and European sales. But it’s ignoring the fact that Fitbit’s Versa smartwatch has clearly rejuvenated the company. (15-0)

What's in the Cards for Fossil Group (FOSL) in Q2 Earnings?

2018-08-06 zacks
The Fossil Group, Inc. (FOSL - Free Report) is expected to report second-quarter 2018 results on Aug 7. In the last reported quarter, this designer and manufacturer of accessories delivered a positive earnings surprise of 5.7%. Further, the bottom line has outperformed the Zacks Consensus Estimate in the trailing four quarters by an average of 54.1%. Let’s see what awaits this quarterly release. (13-0)

Silicon Investor Message Boards

This table lists all message boards related to FOSL / Fossil Group, Inc. on message board site Silicon Investor.

CAMP, FOSL, ZLC, CSCC, Articles CAMP, FOSL, ZLC, CSCC, Articles CAMP, FOSL, ZLC, CSCC, Articles Fossil(FOSL) Fossil(FOSL) Fossil(FOSL)
CUSIP: 34988V106